Next-generation immuno-oncology Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:46
Jan 15
Jan 15
Next-gen immuno-oncology addresses Keytruda's 70% non-responders.
Keytruda helps only about 30% of patients, and the remaining 70% represent the main unmet need in oncology. Big pharma is increasingly focused on next-generation immuno-oncology, with bispecific and cytokine deals validating the shift, so this is a current rather than distant investment theme.
HIGH
About Next-generation immuno-oncology Investor Commentary
Across the available history and selected sources, Buzzberg tracks Next-generation immuno-oncology across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Lee Kyung-ho.